Accessibility Menu
Alpha Tau Medical logo

Alpha Tau Medical(NASDAQ) DRTS

Market Cap$1.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+42%
5 Year+46%
1 Year+369%
1 Month+8%
Premium Feature
Moneyball Superscore
63/100
$14.87
+3.52%
+0.51Today
Alpha Tau Medical last closing stock price
MetricPriceDate
Last closeUSD 14.362026-08-20
Alpha Tau Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.97%USD 14.502026-08-13
1 month+7.81%USD 13.322026-07-21
3 month+43.03%USD 10.042026-05-22
Year to date+190.1%USD 4.952025-12-31
1 year+369.28%USD 3.062025-08-20
3 year+305.65%USD 3.542023-08-21
5 year+46.38%USD 9.812021-08-20
Since inception+42.18%USD 10.102021-03-08

Alpha Tau Medical Financials at a Glance

Market Cap

$1.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$92.57M

EPS (TTM)

-$1.04

P/E Ratio

-13.81

Dividend

$0.00

Beta (Volatility)

0.61 (Low)

Price

$14.87

Volume

161,507.15

Open

$14.57

Previous Close

$14.36

Daily Range

$14.40 - $15.02

52-Week Range

$3.06 - $15.02

Estimated Earnings Date

Nov 19, 2026

DRTS News

Scientists looking at brain scans

Why Alpha Tau Medical Stock Skyrocketed Today

Keith SpeightsMar 24, 2022
alphataumedical

Why Alpha Tau Medical Ltd. Stock Soared 42% on Wednesday

James HalleyMar 23, 2022

DRTS: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing and commercializing diffusing alpha-emitters radiation therapy (Alpha DaRT) for solid cancer treatment. The company is headquartered in Jerusalem, Israel, and is actively engaged in clinical trials for various cancer types.

Products and Services
  • Alpha DaRT technology for treating solid tumors
  • Clinical trials for skin, oral, pancreatic, prostate, lung, liver, and breast cancers
  • Preclinical studies for mouse and human-derived tumors
Growth Outlook
  • Strong pipeline with multiple ongoing clinical trials
  • Potential market expansion as Alpha DaRT technology gains traction
  • Increased interest in innovative cancer therapies from healthcare providers
Financial Highlights
  • Recent quarterly net income of -$45.8 million, reflecting ongoing R&D investments
  • Cash and short-term investments totaling $100.6 million as of June 30, 2026
  • Current ratio of 11.09, indicating strong liquidity position
Alpha Tau Medical Ltd. is positioned in the biotechnology sector, focusing on innovative cancer treatment solutions. The company's Alpha DaRT technology is currently undergoing clinical trials, which could lead to significant advancements in oncology. The strong liquidity position, as evidenced by a current ratio of 11.09, provides a solid foundation for continued research and development efforts. Despite recent net income losses, the ongoing investments in R&D highlight the commitment to advancing cancer treatment options. The potential for market expansion and growing interest in novel therapies further enhances the company's growth outlook.
AI Generated • Aug 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

112

CEO

Uzi Sofer, MBA

Website

www.alphatau.com

Headquarters

Jerusalem, JM 9777605, IL

DRTS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-138.12%

Return on Capital

-46.56%

Return on Assets

-68.96%

Earnings Yield

-7.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

90.33M

Volume

161.51K

Avg. Volume

782.22K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$50.43M

EBITDA

-$49.54M

Operating Cash Flow

-$26.68M

Capital Expenditure

-$6.08M

Free Cash Flow

-$32.76M

Cash & ST Invst.

$100.64M

Total Debt

$15.15M

Alpha Tau Medical Performance Analysis

Alpha Tau Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Alpha Tau Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Alpha Tau Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.53-21.0%
20232023-12-31USD -0.42-20.9%
20242024-12-31USD -0.458.0%
20252025-12-31USD -0.5316.5%
Alpha Tau Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-7.7%
Q42025-12-31N/A
Q12026-03-31-85.7%
Q22026-06-30-92.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.72M

N/A

Employees

121

N/A

Net Income

-$45.81M

-353.0%

EBITDA

-$13.78M

-50.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$100.64M

+26.3%

Total Debt

$15.15M

+13.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$13.84M

+13.1%

Short Term Debt

$1.32M

+21.9%

Return on Assets

-68.96%

N/A

Return on Invested Capital

-40.47%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANROAlto Neuroscience, Inc.
$35.04+2.29%
CADLCandel Therapeutics, Inc.
$12.88+4.29%
LRMRLarimar Therapeutics, Inc.
$4.16-0.12%
DMACDiaMedica Therapeutics Inc.
$6.69+2.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.48+0.06%
JUNSJupiter Neurosciences
$10.62+1.05%
INTCIntel
$90.38-0.02%
MARAMara Holdings
$11.90+0.07%

Questions About DRTS

What is the current price of Alpha Tau Medical?

Alpha Tau Medical is trading at $14.76 per share.

What is the 52-week range for Alpha Tau Medical?

Over the past 52 weeks, Alpha Tau Medical has traded between $3.06 and $15.02.

How much debt does Alpha Tau Medical have?

As of the most recent reporting period, Alpha Tau Medical reported total debt of $15.15M.

How much cash does Alpha Tau Medical have on hand?

Alpha Tau Medical reported $27.13M in cash and cash equivalents in its most recent financial results.

What is Alpha Tau Medical’s dividend yield?

Alpha Tau Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services